Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines

The bone-seeking radiopharmaceutical Xofigo (Radium-223 dichloride) has demonstrated both extended survival and palliative effects in treatment of bone metastases in prostate cancer. The alpha-particle emitter Ra-223, targets regions undergoing active bone remodeling and strongly binds to bone hydro...

Descripción completa

Detalles Bibliográficos
Autores principales: Abramenkovs, Andris, Hariri, Mehran, Spiegelberg, Diana, Nilsson, Sten, Stenerlöw, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489499/
https://www.ncbi.nlm.nih.gov/pubmed/36126563
http://dx.doi.org/10.1016/j.tranon.2022.101543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489499/
https://www.ncbi.nlm.nih.gov/pubmed/36126563
http://dx.doi.org/10.1016/j.tranon.2022.101543

Ejemplares similares